Blueprint Medicines, Inc. (BPMC)

Oncology Corporate Profile

Stock Performance

55.9200
1.3400

HQ Location

215 First Street
Cambridge, MA 2142

Company Description

Blueprint Medicines makes kinase drugs to treat patients with genomically defined diseases. Led by a team of industry innovators, Blueprint Medicines integrates a novel target discovery engine and a proprietary compound library to understand the blueprint of cancer and craft highly selective therapies. This empowers the Blueprint Medicines team to develop patient-defined medicines aimed at eradicating cancer.

Website: http://www.blueprintmedicines.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
BLU-285®PDGFR®D842V inhibitorGastrointestinal Stromal Tumors (GIST)I
BLU-554PDGFR®D842V inhibitorHepatocellular carcinoma (HCC)I
BLU-667RET inhibitorNon Small Cell Lung Cancer (NSCLC)I
BLU-667RET inhibitorThyroid cancerI

Source: http://www.blueprintmedicines.com/

Recent News Headlines

7/24/2017 06:17 pm

7/24/2017 06:17 pm

7/24/2017 06:17 pm

7/24/2017 06:17 pm

7/24/2017 06:17 pm

7/24/2017 12:17 pm

7/24/2017 12:17 pm

7/24/2017 12:17 pm

7/7/2017 12:17 pm

7/7/2017 12:17 pm

7/7/2017 12:17 pm

7/7/2017 12:17 pm

7/6/2017 06:17 am

7/6/2017 06:17 am

7/5/2017 06:17 am

7/5/2017 06:17 am

7/5/2017 06:17 am

7/5/2017 06:17 am

6/19/2017 06:17 pm

6/5/2017 06:17 am

6/1/2017 12:17 pm

6/1/2017 06:17 am

5/17/2017 12:17 pm

5/5/2017 06:17 am

5/3/2017 12:17 am